TSS
SLXN

Two Sigma Securities’s Silexion Therapeutics SLXN Stock Holding History

Two Sigma Securities’s Portfolio SLXN Stock Details SLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,166
Closed -$14.9K – 2499
2026
Q1 		$14.9K Buy
+1,166
New +$20.4K ﹤0.01% 1419
2024
Q4 		– Sell
-11
Closed -$7.94K – 3447
2024
Q3 		$7.94K Buy
+11
New +$17.3K ﹤0.01% 2634

Other funds holding SLXN

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
MA
Montag & Associates Atlanta, Georgia $2.37B AUM 28.86% 1-Year Est. Return
PK
Pflug Koory Omaha, Nebraska $250M AUM 42.29% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Two Sigma Securities's SLXN Position: Q2 2026 in Review

Two Sigma Securities sold out of Silexion Therapeutics (SLXN) in Q2 2026, closing a stake of 1,166 shares — an estimated $14.9K sold.

Two Sigma Securities first reported a position in SLXN in Q3 2024 and held it in 2 quarters. The position peaked at $14.9K in Q1 2026. 6 funds tracked by Wall St. Rank hold SLXN as of Q2 2026.

  • Two Sigma Securities reported no remaining Silexion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Two Sigma Securities sold 1,166 Silexion Therapeutics shares in Q2 2026, an estimated $14.9K.
  • Two Sigma Securities first reported a position in Silexion Therapeutics in Q3 2024 and held it in 2 quarters.
  • Two Sigma Securities's Silexion Therapeutics position peaked at $14.9K in Q1 2026.
  • 6 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.